Diego Cadavid to Multiple Sclerosis, Relapsing-Remitting
This is a "connection" page, showing publications Diego Cadavid has written about Multiple Sclerosis, Relapsing-Remitting.
Connection Strength
1.310
-
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 09; 18(9):845-856.
Score: 0.647
-
Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
Score: 0.412
-
Motl RW, Putzki N, Pilutti LA, Cadavid D. Longitudinal changes in self-reported walking ability in multiple sclerosis. PLoS One. 2015; 10(5):e0125002.
Score: 0.121
-
Qian P, Cadavid D, Wolansky LJ, Cook SD, Naismith RT. Heterogeneity in longitudinal evolution of ring-enhancing multiple sclerosis lesions. Ann Neurol. 2011 Oct; 70(4):668-9; author reply 669-70.
Score: 0.094
-
Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology. 2017 Aug 15; 89(7):714-721.
Score: 0.035